The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

A technology for renal fibrosis and kidney disease, applied in the direction of urinary system diseases, active ingredients of heterocyclic compounds, medical preparations containing active ingredients, etc., can solve problems such as renal fibrosis or CKD that cannot be cured

Pending Publication Date: 2021-02-26
ALGERNON PHARMA INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] There is currently no cure for renal fibrosis or CKD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease
  • The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease
  • The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0119] Materials and Methods

[0120] Male 9-12 week old C57BL / 6 mice weighing 23-25 ​​g were used. All mice were acclimatized for a minimum of 5 days prior to study initiation and were housed individually in microisolators on a 12:12 light-dark cycle throughout the study with standard mouse maintenance chow (Harlan Teklad 2018), chow and Water was obtained ad libitum. Before surgery, all mice were weighed as baseline body weight.

[0121] UUO surgical intervention was performed according to previously described methods known in the art (Le Meur Y et al., Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF / c-fms pathway (Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF / c-fms pathway), J Leukocyte Biol., 72:530-537; 2002).

[0122]All mice were first anesthetized with a rodent mixture (ketamine 10 mg / mL and Xyaline 1 mg / mL) in saline (10 μL / g body weight) by intraperitoneal injection. Pedal reflexes and vibris...

Embodiment 2

[0170] Materials and Methods

[0171] In this example, healthy female young C57BL / 6 mice were used for the study. Mice were between 9-12 weeks of age and weighed 23-25 ​​g at the start of the study. All mice were obtained from Charles River Laboratories.

[0172] Mice were maintained in a controlled environment with a temperature of 70-72°F and a humidity of 30-70%, with a light cycle of 12 hours light and 12 hours dark. Harlan Teklad 2018 standard mouse maintenance chow was provided and water was available ad libitum.

[0173] After five days of acclimatization, mice were grouped according to body weight. Ten groups in total, ten mice in each group. Nine of the ten groups underwent UUO individually, while another of the ten groups underwent sham surgery as a non-operative control, as described above.

[0174] After surgery, the mice were divided into 10 separate study groups of 10 animals and received oral treatment once a day for 14 days after postoperative recovery. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and / or Istradefylline are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.

Description

[0001] Refer to related applications [0002] This application claims priority to U.S. Provisional Patent Application 62 / 690,738, filed June 27, 2018, and U.S. Provisional Application 62 / 809,330, filed February 22, 2019, the contents of which are hereby incorporated by reference. [0003] field of invention [0004] The present invention relates to the use of compounds in treating kidney diseases, in particular to the use of specific compounds in treating renal fibrosis and / or chronic kidney diseases. Background technique [0005] Chronic kidney disease (CKD) is a type of kidney disease in which kidney damage worsens over time, usually as a result of renal fibrosis. This causes a gradual loss of kidney function, allowing excess fluid and waste from the blood to remain in the body and potentially cause other health problems. [0006] Early on, individuals with CKD are often asymptomatic. However, as the disease progresses, symptoms may include muscle cramps, nausea and vomi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/196A61K31/13A61K31/4184A61K31/44A61K31/445A61K31/4741A61K31/519A61K31/522A61P13/12
CPCA61K31/445A61K31/522A61K31/4741A61P13/12A61K31/44A61K31/519A61K31/13A61K31/196A61K31/4184A61K45/06A61K31/4164A61K31/366A61K31/167A61K31/136A61K2300/00A61K38/1816
Inventor M·威廉姆斯
Owner ALGERNON PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap